Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 5/20 | 0.45 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.45 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.45 |
| ▸ | NMBR | P28336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410552 | 0.90 | SOAT1 (0.53) | SOAT1SOAT2ACAT1 | |
| SCHEMBL13083300 | 0.88 | SOAT1 (0.44) | SOAT1SOAT2ACAT1 | |
| SCHEMBL13083184 | 0.87 | SOAT1 (0.41) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL13083298 | 0.86 | SOAT1 (0.42) | SOAT1SOAT2ACAT1 | |
| SCHEMBL3412551 | 0.82 | SOAT1 (0.52) | SOAT1SOAT2ACAT1 | |
| SCHEMBL3404765 | 0.77 | SOAT1 (0.53) | SOAT1SOAT2ACAT1 | |
| SCHEMBL3414055 | 0.77 | SOAT1 (0.48) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL13083283 | 0.77 | SOAT1 (0.41) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL3413997 | 0.75 | SOAT1 (0.49) | SOAT1SOAT2ACAT1 | |
| SCHEMBL9641246 | 0.71 | SOAT1 (0.76) | SOAT1SOAT2ACAT1NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283378-B2 | Phenylurea inhibitors of the SOAT-1 enzyme and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-09 | — | — | US | disclosed |
| US-20100222431-A1 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222431-A1 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | SOAT1, SOAT2, ACAT2 | SOAT1 1/4885SOAT2 2/4885ACAT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.